Results 21 to 30 of about 9,329 (213)

Induction-phase treatment costs for cryptococcal meningitis in high HIV-burden African countries: New opportunities with lower costs [version 3; peer review: 3 approved]

Wellcome Open Research, 2022
Introduction: Access to and the cost of induction treatment for cryptococcal meningitis (CM) is rapidly changing. The newly-announced price for flucytosine ($0.75 per 500 mg pill) and possibly lower prices for liposomal amphotericin B (AmB-L) create ...
Amir Shroufi, Radha Rajasingham, Bruce Larson, Joseph N. Jarvis, Rita Oladele, Charles Muthoga, Tom M. Chiller, Alexander Jordan, Nelesh P. Govender   +8 more
doaj   +1 more source

AMBITION-cm : intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa : study protocol for a randomized controlled trial [PDF]

, 2015
Cryptococcal meningitis (CM) is a leading cause of mortality among HIV-infected individuals in Africa. Poor outcomes from conventional antifungal therapies, unavailability of flucytosine, and difficulties administering 14 days of amphotericin B are key ...
Leeme, Tshepo, Síle F. Molloy, Changalucha, John M., Molefi, Mooketsi, Molloy, Síle F, Meintjes, Graeme, Molloy, Síle F., Goldberg, Drew W, John R. Perfect, Drew W. Goldberg, Kalluvya, Samuel, Cainelli, Francesca, Letang, Emili, Ndhlovu, Chiratidzo E, Perfect, John R, Ndhlovu, Chiratidzo E., Bisson, Gregory P., Miriam Haverkamp, Burton, Rosie, Rosie Burton, Tariro Makadzange, Harrison, Thomas S, Francesca Cainelli, Hope, William, Haverkamp, Miriam, Chiratidzo E. Ndhlovu, Harrison, Thomas S., Jarvis, Joseph N., Chofle, Awilly A, William Hope, Jarvis, Joseph N, Changalucha, John M, Fenner, Lukas, Perfect, John R., Makadzange, Tariro, Joseph N. Jarvis, Tshepo Leeme, Mooketsi Molefi, Nametso Lekwape, Lekwape, Nametso, John M. Changalucha, Emili Letang, Goldberg, Drew W., Lukas Fenner, Bisson, Gregory P, Awilly A. Chofle, Samuel Kalluvya, Thomas S. Harrison, Graeme Meintjes, Chofle, Awilly A., Gregory P. Bisson   +50 more
core   +1 more source

Antifungal Drugs

Metabolites, 2020
We reviewed the licensed antifungal drugs and summarized their mechanisms of action, pharmacological profiles, and susceptibility to specific fungi. Approved antimycotics inhibit 1,3-β-d-glucan synthase, lanosterol 14-α-demethylase, protein ...
Jiří Houšť, Jaroslav Spížek, Vladimír Havlíček   +2 more
doaj   +1 more source

New Horizons in Antifungal Therapy

Journal of Fungi, 2016
Recent investigations have yielded both profound insights into the mechanisms required by pathogenic fungi for virulence within the human host, as well as novel potential targets for antifungal therapeutics.
Kaila M. Pianalto, J. Andrew Alspaugh
doaj   +1 more source

Quantitative and qualitative analysis of the antifungal activity of allicin alone and in combination with antifungal drugs. [PDF]

PLoS ONE, 2012
The antifungal activity of allicin and its synergistic effects with the antifungal agents flucytosine and amphotericin B (AmB) were investigated in Candida albicans (C. albicans). C.
Young-Sun Kim, Kyung Sook Kim, Ihn Han, Mi-Hyun Kim, Min Hyung Jung, Hun-Kuk Park   +5 more
doaj   +1 more source

In Vitro Characterization of Twenty-One Antifungal Combinations against Echinocandin-Resistant and -Susceptible Candida glabrata

Journal of Fungi, 2021
This study was designed to analyze the interaction of 21 antifungal combinations consisting of seven major antifungal agents against 11 echinocandin- susceptible and six-resistant C. glabrata isolates. The combinations were divided into five major groups
Hazim O. Khalifa, Hidetaka Majima, Akira Watanabe, Katsuhiko Kamei   +3 more
doaj   +1 more source

Short-Course Rather Than Low-Dose Amphotericin B May Exert Potential Influence on Mortality in Cryptococcal Meningitis Patients Treated With Amphotericin B Plus Flucytosine Alone or in Combination With Fluconazole

Frontiers in Microbiology, 2019
BackgroundThe influence of Amphotericin B (AmB) dose and the addition of fluconazole (Flu) on the AmB + 5-flucytosine (5FC) regimen for cryptococcal meningitis (CM) treatment remain debatable.MethodsA retrospective study was conducted to compare 44 CM ...
Lijun Xu, Lijun Xu, Ran Tao, Ran Tao, Jingjing Wu, Xiahong Dai, Caiqin Hu, Ying Huang, YaoKai Chen, Biao Zhu, Biao Zhu, Jianqin He, Jianqin He   +12 more
doaj   +1 more source

Does DHN-Melanin Always Protect Fungi against Antifungal Drugs? The Fonsecaea/Micafungin Paradigm

Microbiology Research, 2022
Several human pathogenic fungi produce melanin. One of its properties during parasitism is the protection against antifungal drugs. This occurs with the agents of chromoblastomycosis, in which DHN-melanin reduces antifungal susceptibility to terbinafine ...
Rowena Alves Coelho, Maria Helena Galdino Figueiredo-Carvalho, Juliana Vitória dos Santos Silva, Dario Correa-Junior, Susana Frases, Rosely Maria Zancopé-Oliveira, Dayvison Francis Saraiva Freitas, Rodrigo Almeida-Paes   +7 more
doaj   +1 more source

Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal.

, 2013
Current, widely accepted guidelines for the management of HIV-associated cryptococcal meningoencephalitis (CM) recommend amphotericin B combined with flucytosine (5-FC) for ≥2 weeks as the initial induction treatment of choice.
A. Loyse, Dromer, F, Day, J, Lortholary, O, O. Lortholary, Harrison, TS, F. Dromer, Day, Jeremy, T. S. Harrison, J. Day, Loyse, A   +10 more
core   +1 more source

Antifungal Susceptibility of Saccharomyces cerevisiae Isolated from Clinical Specimens

Pathogens
(1) Background: Despite being considered a non-pathogenic yeast, recently, a growing occurrence of Saccharomyces cerevisiae infections has been noted. There is little knowledge about the drug susceptibility of this species.
Aleksandra Górzyńska, Kamila Kondracka, Agnieszka Korzeniowska-Kowal, Urszula Nawrot   +3 more
doaj   +1 more source